[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637912":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":59,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":25,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":25,"overallStatus":81,"whyStopped":25,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Methotrexate","ACTIVE_COMPARATOR","Group 1 : 35 of patients with early undisturbed ectopic pregnancy will receive methotrexate (1mg\\\\kg IM) and follow up by β-hCG on day 4 and day 7 of first dose at Clinical Pathology Department ., Faculty of Medicine, Kafrelsheikh University Hospitals. At day 7 If β-hCG decrease \\>15% than day 4 , β-hCG will be repeated weekly till negative but If β-hCG decrease \\\u003C 15% than day 4 second dose of methotrexate will be given 50mg\u002Fm2 IM and follow up weekly (maximum dose is 4 doses) .",[13],"Drug: Methotrexate (drug)",{"label":15,"type":10,"description":16,"interventionNames":17},"Letrozole","Groub 2 : 35 of patients with early undisturbed ectopic pregnancy will receive letrozole (2.5 mg three times daily) for 10 days and follow up by β-hCG on day 4 and day 7 of first dose at Clinical Pathology Department, Faculty of Medicine, Kafrelsheikh University Hospitals . Patients who had no success response to letrozole (β-hCG not decreased by 30% after 10 days ) , laparoscopy will be done .",[18],"Drug: Letrozole 2.5Mg Tab",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Methotrexate (drug)","Methotrexate is a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, which converts folic acid to tetrahydrofolate, a cofactor needed in DNA and RNA synthesis",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Letrozole 2.5Mg Tab","Aromatase inhibitors has been shown toSuccessfully block estrogen production In the absence of estrogen priming, progesterone may not exert its physiological functions due to a negative effect on progesterone receptors. It was hypothesized that by inhibiting the estrogen synthetase (the aromatase enzyme), the progesterone would not exert its physiological function in maintaining pregnancy, including ectopic pregnancy",[15],[31],{"name":32,"affiliation":33,"role":34},"Walid Mamdouh Atallah, OBGYN Professor","Tanta University","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Aya Fekry Saad Bahnasy, Obstetrics&Gynecology resident","CONTACT","+201092178164","ayafekry772@gmail.com",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Mostafa Farag Ellakany, Obstetrics&Gynecology Lecturer","+2010116083210","mfe_2014@yahoo.com",[46],{"facility":47,"status":25,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":25},"Kafr El-Sheikh University","Kafr ash Shaykh","Kafr el-Sheikh Governorate","33511","Egypt","EG",{"type":54,"coordinates":55},"Point",[56,57],30.93991,31.11174,{"lat":57,"lon":56},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Aya fekry saad bahnasy","Principal Investigator","100637912","phase-2-letrozole-versus-methotrexate-for-management-of-undisturbed-ectopic-pregnancy-100637912",false,"NCT07624903","Letrozole Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy","Inclusion Criteria:\n\n* Confirmed ectopic pregnancy on trans vaginal ultrasound\n* Age between 20 and 35 years\n* A β-hCG levels \\\u003C 3000 Iu\u002F L\n* The average diameter of the adnexal mass ≤3.5 cm\n* Stable hemodynamic condition\n\nExclusion Criteria:\n\n* Presence of fetal heart pulsation\n* Heterotopic pregnancy\n* Presence of significant abdominal pain\n* history of allergic reactions to MTX or letrozole\n* Any known liver disorder or abnormal liver enzyme levels (AST or ALT )\n* Any known renal disorder or impaired renal function tests (abnormal creatinine)","FEMALE","20 Years","35 Years",{"count":73,"type":74},70,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","The aim of work is to study the effectiveness of letrozole in treatment of early undisturbed ectopic pregnancy in comparison with Methotrexate.",[80],"Ectopic Pregnancy","NOT_YET_RECRUITING","2026-05-30",{"date":84,"type":85},"2026-06-03","ACTUAL",{"date":87,"type":74},"2026-06",{"date":89,"type":74},"2027-07",{"name":5,"class":6},1]